Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide

Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications.

To report ophthalmic complications associated with the use of semaglutide or tirzepatide. Design, Setting, and Participants: This was a retrospective case series. All patients were initially seen in a community setting. Patients experiencing an ophthalmic complication in association with the use of semaglutide or tirzepatide were included in this analysis. Exposures: Patients described were using either semaglutide or tirzepatide. Main Outcomes and Measures: Visual acuity and visual field defects.